Skip to main content

$0.005 (0.00%)

High

$0.01

Low

$0.01

Trades

3

Turnover

$2,010

Volume

402,075
30 June 2023 at 11:45am
Register to track AVE and receive email alerts.

Phase I clinical trial testing CBD product-enrolment begins

StockBot

416,823 posts

AVE released this announcement to the ASX on 15 September 2021, 8:46. The announcement is marked as price sensitive, and is 3 page(s) in length and 72.69kb in size.

You can view all announcements from AVE and see how they appear on a price chart on the announcements page.

At the date of this announcement, AVE was 0.001% short sold according to ASIC data. It was ranked the 623rd most shorted stock on the ASX. It remains ranked 623rd as of the latest reported data (10 February 2025).

Other Recent Announcements from AVE
Update - Application for quotation of securities - AVE 28 June 2023, 11:48
Application for quotation of securities - AVE 28 June 2023, 11:43
AVE CBD capsule passes two-year stability milestone 22 June 2023, 8:57
Phase I clinical trial testing CBD product-enrolment begins 15 September 2021, 8:46
Change of Director's Interest Notice 10 September 2021, 17:04
Notification of cessation of securities - AVE 10 September 2021, 17:01
Appendix 4D and Half-year Financial Report 24 August 2021, 8:41
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track AVE and receive email alerts.